About DUSA Pharma
DUSA Pharma is a Healthcare company based in Wilmington (United States) founded in 1991, and was acquired by Sun Pharma in November 2012. Dermatology products for actinic keratosis and acne. DUSA Pharma has raised $42.75 million across 1 funding round from investors including Sun Pharma and Invesco. Its chief executive, as recorded, is Robert F Doman. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is Sun Pharmaceutical Industries, Inc. Its competitors include Revance Therapeutics, Castle Creek Pharma and Dermavant; 3 of its 3 listed competitors have raised funding.
Company details
DUSA Pharmaceuticals was founded in 1991 and is headquartered in Wilmington, United States. Operations center on the specialty pharmaceutical sector, with emphasis on dermatology treatments. The Levulan photodynamic therapy platform, used alongside the BLU-U blue light illuminator, is developed and marketed for FDA-approved treatment of actinic keratoses on the face or scalp. The BLU-U device is also applied independently for mild to moderate inflammatory acne management.
- Headquarters Wilmington, United States
- Stage Acquired
- SectorsHealthcare
- Website dusapharma.com
- Social LinkedIn X
- Acquired by Sun Pharma (Nov 2012)
- Legal Name Sun Pharmaceutical Industries, Inc.
- Total Equity Funding$42.75M (USD)
in 1 rounds
- Latest Funding Round$42.75M (USD), Series C
Feb 2000
- InvestorsSun Pharma
& 1 more
- Acquired bySun Pharma
(Nov 2012)
Funding Insights of DUSA Pharma
DUSA Pharma has successfully raised a total of $42.75M through 1 strategic funding round. The most recent funding activity was a Series C round of $42.75 million completed in February 2000. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.75M
- Total Rounds 1
- Last Round Series C — $42.75M
- First Round $42.75M
(Feb 2000)
- Investors Count 1
All 1 funding rounds of DUSA Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2000 | $42.75M | Series C | – | – |
2 investors in total: 2 institutional.
Investors in DUSA Pharma
DUSA Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Sun Pharma and Invesco.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified asset management services are offered globally by Invesco. | invesco.com | Atlanta, United States | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | sunpharma.com | Mumbai, India |
Investor details for DUSA Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of DUSA Pharma
1 people are tracked at DUSA Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Robert F Doman | CEO & President | Leadership |
Complete people profiles for DUSA Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of DUSA Pharma
3 dated milestones of DUSA Pharma across 21 years, from founding to its latest funding, stage changes and deals.
- Founded DUSA Pharma is founded.
- Funding First funding round of $42.8M.
- Exit Acquired by Sun Pharma.
Competitors of DUSA Pharma
DUSA Pharma has 3 listed competitors in our database, 3 of them funded. They include Revance Therapeutics, Castle Creek Pharma and Dermavant.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revance.com | 2002 | Newark, United States | $154.56M | 597 | Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | |
| castlecreekpharma.com | 2015 | Basking Ridge, United States | $663.15M | 72 | Drugs for skin diseases, ENT disorders, and rare diseases such as urea cycle disorders | |
| dermavant.com | 2016 | Phoenix, United States | $160M | Small molecule therapeutics for inflammatory skin diseases are developed. |
Detailed competitors of DUSA Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of DUSA Pharma
Websites that share an audience with DUSA Pharma (dusapharma.com).
Websites whose visitors overlap most with DUSA Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
liaoyuan.com.cn | liaoyuan.com.cn | 100% | – | ||
| medicis.com | 100% | View details | |||
tabcoat.com | tabcoat.com | 100% | – | ||
mundipharma.net | mundipharma.net | 100% | – | ||
| cap-m-quik.com | 100% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for DUSA Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Dermatology
3 companies that operate in the same segment as DUSA Pharma (Dermatology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Neurotoxin products for aesthetic and therapeutic skin treatments are developed. | 2002 | Newark, New Jersey, United States | USD 154.56 M | USD 234.04 M | 597 | |
Diagnostic tests for cancer prognosis are provided. | 2008 | Friendswood, Texas, United States | USD 61.97 M | USD 344.23 M | 761 | |
Adhesive patch biopsies for skin cancer detection are provided. | 1996 | San Diego, California, United States | USD 24.37 M | USD 15.3 M | 259 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dusa Pharma
Complete news archive for DUSA Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DUSA Pharma
DUSA Pharma was founded in 1991 and raised its 1st funding round 9 years after it was founded.
DUSA Pharma is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware, United States.
Robert F Doman is the CEO of DUSA Pharma, as recorded in our data.
DUSA Pharma is a funded company, having raised a total of $42.75M across 1 funding round to date. The company's 1st funding round was a Series C of $42.75M, raised on Feb 2000.
DUSA Pharmaceuticals was founded in 1991 and is headquartered in Wilmington, United States. Operations center on the specialty pharmaceutical sector, with emphasis on dermatology treatments. The Levulan photodynamic therapy platform, used alongside the BLU-U blue light illuminator, is developed and marketed for FDA-approved treatment of actinic keratoses on the face or scalp. The BLU-U device is also applied independently for mild to moderate inflammatory acne management.
DUSA Pharma's top competitors include Revance Therapeutics, Dermavant and Castle Creek Pharma.
DUSA Pharma has 2 investors. Key investors include Sun Pharma, and Invesco.
DUSA Pharma operates through Sun Pharmaceutical Industries, Inc..
Yes. DUSA Pharma was acquired by Sun Pharma in November 2012.